GlassScriptPhysician profile
Sabah Mohyaddin Mohammed
NPI 1366484206
$2,114.68
in general payments reported to CMS, 2019-2025
26 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $59.91 · 2021: $17.80 · 2022: $178 · 2023: $580 · 2024: $656 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $471.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $188.24 | 2019-2024 | |
| Glaxosmithkline, LLC. | $148.57 | 2023-2025 | Trelegy Ellipta |
| Abbvie INC. | $138.05 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $131.65 | 2019-2020 | |
| Pfizer INC. | $123.37 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.69 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $92.32 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $87.08 | 2022-2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $69.57 | 2023-2024 | Breztri, Fasenra, Lokelma |
| Aimmune Therapeutics, INC. | $57.36 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.15 | 2022-2023 | Ofev |
| Sanofi-Aventis U.S. LLC | $49.15 | 2024-2025 | |
| Lilly USA, LLC | $45.47 | 2024 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $44.22 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $40.17 | 2024 | Austedo Xr |
| Amgen INC. | $38.01 | 2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $35.27 | 2022 | |
| Nestle Healthcare Nutrition INC. | $31.13 | 2023 | |
| Stryker Corporation | $28.23 | 2025 | Clottriever Bold Catheter |
| Boston Scientific Corporation | $26.60 | 2023 | Watchman Flx |
| Alkermes, INC. | $21.94 | 2025 | Aristada, Lybalvi |
| Acadia Pharmaceuticals INC | $21.64 | 2022 | |
| Bausch Health US, LLC | $20.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.02 | 2023 | Eliquis |
| Ibsa Pharma INC. | $15.06 | 2025 | Licart, Flector, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabah Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.